SusanneRachelGoldsteinMD

PubMed

• 43 citations
  Anxiety and self-perceived health status in Parkinson's disease.
  Gregory M. Pontone, James Williams, Karen E. Anderson, Gary A. Chase, Susanne R. Goldstein
  Parkinsonism & Related Disorders. 2011-05-01
• 3 citations
  Application of depression rating scales in patients with Parkinson's disease with and without co-Occurring anxiety
  Jessica Calleo, James Williams, Amber B. Amspoker, Leah Swearingen, Elaina S. Hirsch
  Journal of Parkinson's Disease. 2013-01-01
• 93 citations
  A comparison of nine scales to detect depression in Parkinson disease: Which scale to use?
  James Williams, Elaina S. Hirsch, Karen E. Anderson, A.L. Bush, Susanne R. Goldstein
  Neurology. 2012-03-27

Journal Articles

• Prevalence of Anxiety Disorders and Anxiety Subtypes in Patients with Parkinson’s Disease  
  Pontone GM, Williams JR, Anderson KE, Chase G, Goldstein SR, Grill S, Hirsh ES, Lemann S, Little JT, Margolis RL, Rabins PV, Weiss HD, Marsh L, Move Disord, 7/1/2009
• Adult-onset primary lower limb dystonia  
  Schneider SA, Edwards MJ,Grill SE, Goldstein S, Knachana S, Quinn NP, Bhatia KP, Hallett M, Reich SG, Mov Disord, 1/1/2006
• Pilot Trial of 1-Octanol in Essential Tremor  
  Bushara KO, Goldstein SR, Grimes, GJ, Bernstein A, Hallett, M, Neurology, 1/1/2003
• Accelerometry to distinguish psychogenic from essential tremor or parkinsonian tremor  
  Zeuner KE, Shoge RO, Goldstein SR, Dambrosia JM. Hallett, M, Neurology
• Somatosensory evoked potentials as a marker of disease burden in type 3 Gaucher disease  
  Garvey MA, Toro C, Goldstein S, Altarescu C, Wiggs EA, Hallett M, Schiffmann R, Neurology
• Hemi-Parkinsonism due to midbrain arteriovenous malformation: dopamine transporter imaging  
  Goldstein S, Friedman JH, Innis R, Seibyl J, Marek K, Mov Disord
• Clozapine for the treatment of generalized and focal dystonia  
  Karp BI, Goldstein SR, Chen R, Bara-Jiminez W, Hallett M, Mov Disord
• Effect of muscle activity immediately after botulinum toxin injection for writer’s cramp  
  Chen R, Karp BI, Goldstein SR, Bara-Jiminez W, Yaseen Z, Hallett M, Mov Disord
• Substituting clzapine for olanzapine in psychiatrically stable Parkinson’s patients: results of an open-label pilot study  
  Friedman JH, Goldstein S, Jacues C, Clin Neuropharmacol
• Autoradiographic distribution of [3H]-(+)-pentazocine binding sites in guinea pig brain  
  Walker JM, Bowen WD, Goldstein SR, Roberts AH, Patrick SL, Hohmann AG, Decosta B, Brain Res
• Motor effects of two sigma ligands mediated by nogrostriatal dopamine neurons  
  Goldstein SR, Matsumoto RR, Thompson TL, Patrick RL, Bowen WD, Walker JM, Synapse
• Conazepam v. alprazolam in the treatment of panic disorder: interim analysis of data from a prospective double-blind, placebo-controlled trial  
  Tesar GE, Rosenbaum JF, Pollack MH, Herman JB, Sachs GS, Mahoney EM, Cohen LS, McNamara M, Goldstein SR, J Clin Psychiatry
• Taurine transport by the flounder (Pseudopleuronectes americanus) intestine  
  King PA, Goldstein SR, Goldstein JM, Goldstein L, J. of Exp. Zoology
• Join now to see all

Books/Book Chapters

• Diseases of the Central Nervous System 
  Chapter: Dystonia 
  Karp, BI, Goldstein S, Hallett MEditors: Asbury A, McKhann G, McDonald WI, Goadsby PJ, McArthur JC.Cambridge University PressEdition Thir,2002

Abstracts/Posters

• Prevalence and comorbidity of psychiatric diagnoses in a community-based sample of patients with Parkinson’s disease (PD)
  Marsh, L, Hirsh ES, Anderson, KE, Goldstein, SR, Grill, S, Lehmann S, Little, JT, Margolis, RL, Palanci, J, Pontone, GM, Rabins, PV, Weiss, HW, Williams, JR, 24th Annual PSG Symposium on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders, Irving, TX, 5/15/2010
• Clozapine for the treatment of generalized and focal dystonia
  Goldstein SR, Karp BI, Sami A, Chen R, Bara-Jiminez W, Hallett M, 5th International Congressof Parkinson’s Disease and Movement Disorders, New York, 10/13/1998
• Substituting olanzapine for clozapine in Parkinson’s disease patients with drug-induced psychosis
  Friedman JH, Goldstein SR, Jacques, European Society for Clinical Neuropharmacology, Eliat, Israel, 12/1/1997
• Dopamine transporter imaging reduced in brainstem hemorrhage
  Goldstein SR, Friedman JH, Marek K, Parkinson’s Study Group, Miami, FL, 10/1/1996
• BCLOZ: Adouble-blind, crossover trial comparing clozapine with benztropine for treatment in Parkinson’s disease
  Friedman JH, Koller W, Goldstein SR, Lannon M, Wilterdink J, American Academy of Neurology, San Francisco, CA, 3/1/1996
• Psychosis and Parkinsonism in a young patient with Down’s syndrome
  Goldstein SR, Neeper R, Glitzke, Gascon GG, American Neuropsychiatric Association, Pittsburgh, PA, 10/1/1995
• Join now to see all

Lectures

• Meeting the Challenges of Parkinson’s disease in Our Community 
  Ellicott City, MD - 4/1/2008
• Parkinson’s disease: Current management 
  Brown University, Providence, RI - 11/11/2006
• ACP-103 for drug-induced psychosis: Update on clinical trial 
  San Diego, CA - 4/1/2006
• Parkinson’s disease: Pathophysiology, Diagnosis, and Treatment 
  MD - 11/9/2005
• Use of botulinum toxin in spasticity 
  Howard County General Hospital, Columbia, MD - 4/1/2002
• Focal dystonia: diagnosis and treatment 
  Howard County General Hospital, Columbia, MD - 4/1/2002
• Neurology: Anatomy and clinical correlation of CNS 
  Brown University, Providence RI - 2/1/2001
• Neuroleptic-induced parkinsonism 
  Memorial Hospital of RI, Brown University, Pawtucket RI - 2/1/1997
• Prion Diseases: Can they cross the species barrier? 
  RI Hospital, Providence RI - 5/1/1996
• Join now to see all